Preoperative Oral Rofecoxib Reduces Postoperative Pain and Tramadol Consumption in Patients After Abdominal Hysterectomy
- 1 April 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 98 (4) , 1039-1043
- https://doi.org/10.1213/01.ane.0000103295.31539.a7
Abstract
We designed this study to determine whether the administration of a preoperative dose of rofecoxib to patients undergoing abdominal hysterectomy would decrease patient-controlled analgesia (PCA) tramadol use or enhance analgesia. Sixty patients were randomized to receive either oral placebo or rofecoxib 50 mg 1 h before surgery. All patients received a standard anesthetic protocol. Intraoperative blood loss was determined. At the end of surgery, all patients received tramadol IV via a PCA-device. Pain scores, sedation scores, mean arterial blood pressure, heart rate, and peripheral oxygen saturation were assessed at 1, 2, 4, 6, 8, 12, and 24 h after surgery. Total and incremental tramadol consumption at the same times was recorded from the PCA-device. Antiemetic requirements and adverse effects were noted during the first postoperative 24 h. Duration of hospital stay was also recorded. The pain scores were significantly lower in the rofecoxib group compared with the placebo group at 6 times during the first 12 postoperative h (P < 0.05). The total consumption of tramadol (627 +/- 69 mg versus 535 +/- 45 mg; P < 0.05) and the incremental doses at 1, 2, 4, 6, 8, and 12 h after surgery were significantly more in the placebo group than in the rofecoxib group. There were no differences between groups in intraoperative blood loss, sedation scores, hemodynamic variables, peripheral oxygen saturation, antiemetic requirements, or adverse effects after surgery. The length of hospital stay was also similar in the groups. We conclude that the preoperative administration of oral rofecoxib provided a significant analgesic benefit and decreased the opioid requirements in patients undergoing abdominal hysterectomy. This study was designed to determine whether the administration of a preoperative dose of rofecoxib to patients undergoing abdominal hysterectomy would decrease patient-controlled analgesia tramadol use or enhance analgesia. We conclude that the preoperative administration of oral rofecoxib provided a significant analgesic benefit and decreased the opioid requirements in patients undergoing abdominal hysterectomy.Keywords
This publication has 16 references indexed in Scilit:
- Effect of Parecoxib, A Novel Intravenous Cyclooxygenase Type-2 Inhibitor, on the Postoperative Opioid Requirement and Quality of Pain ControlAnesthesiology, 2002
- Acute pain management: unmet needs and new advances in pain managementEuropean Journal of Anaesthesiology, 2002
- Effect of peri‐ and postoperative epidural anaesthesia on pain and gastrointestinal function after abdominal hysterectomyBritish Journal of Anaesthesia, 2001
- Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trialJournal of Clinical Anesthesia, 2001
- COX-2???Specific Inhibitors: Definition of a New Therapeutic ConceptClinical Journal of Sport Medicine, 2001
- Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trialClinical Therapeutics, 1999
- Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain modelClinical Pharmacology & Therapeutics, 1999
- Rectal Diclofenac Analgesia after Abdominal HysterectomyAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1997
- Postoperative opioid analgesia: Time for a reconsideration?Journal of Clinical Anesthesia, 1996
- The Value of ???Multimodal??? or ???Balanced Analgesia??? in Postoperative Pain TreatmentAnesthesia & Analgesia, 1993